Blujepa

Overview

gepotidacin

bacterial topoisomerase II inhibitor

• CYP3A4 substrate
• CYP3A4 inhibitor, weak
• P-gp inhibitor, weak
• affected by altered gastrointestinal motility
• alters GI flora
• cholinergic effects
• impairs immunomodulatory bacterial infective agent
• neuromuscular blocking effects
• prolongs QT interval (conditional)

Contraindicated

• cisapride
Blujepa (gepotidacin)

+

cisapride

1 interaction

Contraindicated

gepotidacin + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• colchicine
Blujepa (gepotidacin)

+

colchicine

1 interaction

Contraindicated

gepotidacin + colchicine

CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, consider decr. colchicine dose during and x14 days after gepotidacin use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• eliglustat
Blujepa (gepotidacin)

+

eliglustat

1 interaction

Contraindicated

gepotidacin + eliglustat

CYP2D6 EM: contraindicated if Child-Pugh Class A and if also combined w/ moderate or strong CYP2D6 inhibitor; if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 IM: if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• pimozide
Blujepa (gepotidacin)

+

pimozide

1 interaction

Contraindicated

gepotidacin + pimozide

contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• posaconazole
Blujepa (gepotidacin)

+

posaconazole

1 interaction

Contraindicated

gepotidacin + posaconazole

contraindicated: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• thioridazine
Blujepa (gepotidacin)

+

thioridazine

1 interaction

Contraindicated

gepotidacin + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

• adagrasib
Blujepa (gepotidacin)

+

adagrasib

1 interaction

Avoid/Use Alternative

gepotidacin + adagrasib

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• amikacin
Blujepa (gepotidacin)

+

amikacin

2 interactions

Avoid/Use Alternative

gepotidacin + amikacin

avoid combo: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, both drugs exhibit partial neuromuscular blockade)

• amikacin inhaled
Blujepa (gepotidacin)

+

amikacin inhaled

1 interaction

Avoid/Use Alternative

gepotidacin + amikacin inhaled

avoid combo: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, both drugs exhibit partial neuromuscular blockade)

• amiodarone
Blujepa (gepotidacin)

+

amiodarone

1 interaction

Avoid/Use Alternative

gepotidacin + amiodarone

use alternative or monitor ECG, electrolytes: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• anagrelide
Blujepa (gepotidacin)

+

anagrelide

1 interaction

Avoid/Use Alternative

gepotidacin + anagrelide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apalutamide
Blujepa (gepotidacin)

+

apalutamide

2 interactions

Avoid/Use Alternative

gepotidacin + apalutamide

avoid combo: combo may decr. gepotidacin levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• apixaban
Blujepa (gepotidacin)

+

apixaban

1 interaction

Avoid/Use Alternative

gepotidacin + apixaban

ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• apomorphine
Blujepa (gepotidacin)

+

apomorphine

1 interaction

Avoid/Use Alternative

gepotidacin + apomorphine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aprepitant
Blujepa (gepotidacin)

+

aprepitant

1 interaction

Avoid/Use Alternative

gepotidacin + aprepitant

aprepitant single dose-regimen OK; UROGENITAL GONORRHEA: if aprepitant 3-day regimen, use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: if aprepitant 3-day regimen, consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• arsenic trioxide
Blujepa (gepotidacin)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

gepotidacin + arsenic trioxide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Blujepa (gepotidacin)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

gepotidacin + artemether/ lumefantrine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asenapine
Blujepa (gepotidacin)

+

asenapine

1 interaction

Avoid/Use Alternative

gepotidacin + asenapine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• atazanavir
Blujepa (gepotidacin)

+

atazanavir

1 interaction

Avoid/Use Alternative

gepotidacin + atazanavir

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• azithromycin
Blujepa (gepotidacin)

+

azithromycin

2 interactions

Avoid/Use Alternative

gepotidacin + azithromycin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• BCG live intravesical
Blujepa (gepotidacin)

+

BCG live intravesical

1 interaction

Avoid/Use Alternative

gepotidacin + BCG live intravesical

avoid combo: combo may decr. BCG live intravesical efficacy (antibacterial effect may interfere with BCG activity)

• bedaquiline
Blujepa (gepotidacin)

+

bedaquiline

1 interaction

Avoid/Use Alternative

gepotidacin + bedaquiline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• berotralstat
Blujepa (gepotidacin)

+

berotralstat

1 interaction

Avoid/Use Alternative

gepotidacin + berotralstat

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• bosentan
Blujepa (gepotidacin)

+

bosentan

2 interactions

Avoid/Use Alternative

gepotidacin + bosentan

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• bremelanotide
Blujepa (gepotidacin)

+

bremelanotide

1 interaction

Avoid/Use Alternative

gepotidacin + bremelanotide

avoid combo: combo may decr. peak gepotidacin levels, efficacy (absorption delayed, possibly decreased)

• butalbital
Blujepa (gepotidacin)

+

butalbital

1 interaction

Avoid/Use Alternative

gepotidacin + butalbital

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• cabozantinib
Blujepa (gepotidacin)

+

cabozantinib

1 interaction

Avoid/Use Alternative

gepotidacin + cabozantinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• carbamazepine
Blujepa (gepotidacin)

+

carbamazepine

1 interaction

Avoid/Use Alternative

gepotidacin + carbamazepine

avoid combo: combo may incr. carbamazepine levels, risk of adverse effects; may decr. gepotidacin levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• cenobamate
Blujepa (gepotidacin)

+

cenobamate

2 interactions

Avoid/Use Alternative

gepotidacin + cenobamate

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• ceritinib
Blujepa (gepotidacin)

+

ceritinib

1 interaction

Avoid/Use Alternative

gepotidacin + ceritinib

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• chloramphenicol
Blujepa (gepotidacin)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

gepotidacin + chloramphenicol

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• chloroquine
Blujepa (gepotidacin)

+

chloroquine

1 interaction

Avoid/Use Alternative

gepotidacin + chloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cholera vaccine, live
Blujepa (gepotidacin)

+

cholera vaccine, live

2 interactions

Avoid/Use Alternative

gepotidacin + cholera vaccine, live

avoid vaccine until at least 14 days after gepotidacin course complete: combo may result in inadequate vaccine response (antibiotic effect may inactivate vaccine)

• ciprofloxacin
Blujepa (gepotidacin)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

gepotidacin + ciprofloxacin

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• citalopram
Blujepa (gepotidacin)

+

citalopram

1 interaction

Avoid/Use Alternative

gepotidacin + citalopram

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clarithromycin
Blujepa (gepotidacin)

+

clarithromycin

1 interaction

Avoid/Use Alternative

gepotidacin + clarithromycin

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• clofazimine
Blujepa (gepotidacin)

+

clofazimine

1 interaction

Avoid/Use Alternative

gepotidacin + clofazimine

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• cobicistat
Blujepa (gepotidacin)

+

cobicistat

2 interactions

Avoid/Use Alternative

gepotidacin + cobicistat

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• codeine
Blujepa (gepotidacin)

+

codeine

1 interaction

Avoid/Use Alternative

gepotidacin + codeine

use alternative or monitor resp. rate, consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite morphine)

• colistimethate
Blujepa (gepotidacin)

+

colistimethate

1 interaction

Avoid/Use Alternative

gepotidacin + colistimethate

use alternative or monitor resp. rate: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, both drugs exhibit partial neuromuscular blockade)

• conivaptan
Blujepa (gepotidacin)

+

conivaptan

1 interaction

Avoid/Use Alternative

gepotidacin + conivaptan

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes during and x7 days after conivaptan tx; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes during and x7 days after conivaptan tx: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metab. inhibited)

• crizotinib
Blujepa (gepotidacin)

+

crizotinib

1 interaction

Avoid/Use Alternative

gepotidacin + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• cyclosporine
Blujepa (gepotidacin)

+

cyclosporine

1 interaction

Avoid/Use Alternative

gepotidacin + cyclosporine

UROGENITAL GONORRHEA: use alternative or monitor cyclosporine levels, renal fxn, ECG, electrolytes; URINARY TRACT INFECTION: monitor cyclosporine levels, renal fxn; consider monitoring ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• dabigatran
Blujepa (gepotidacin)

+

dabigatran

2 interactions

Avoid/Use Alternative

gepotidacin + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)

• dabrafenib
Blujepa (gepotidacin)

+

dabrafenib

1 interaction

Avoid/Use Alternative

gepotidacin + dabrafenib

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• danazol
Blujepa (gepotidacin)

+

danazol

1 interaction

Avoid/Use Alternative

gepotidacin + danazol

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• degarelix
Blujepa (gepotidacin)

+

degarelix

2 interactions

Avoid/Use Alternative

gepotidacin + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Blujepa (gepotidacin)

+

desflurane

1 interaction

Avoid/Use Alternative

gepotidacin + desflurane

use alternative or monitor ECG, electrolytes, resp. rate: combo may incr. risk of QT prolongation, cardiac arrhythmias, resp. depression, potentiate, prolong neuromuscular blockade (additive effects, gepotidacin exhibits partial neuromuscular blockade)

• desipramine
Blujepa (gepotidacin)

+

desipramine

1 interaction

Avoid/Use Alternative

gepotidacin + desipramine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine
Blujepa (gepotidacin)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

gepotidacin + dexmedetomidine

use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Blujepa (gepotidacin)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

gepotidacin + dexmedetomidine injection

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• diltiazem
Blujepa (gepotidacin)

+

diltiazem

2 interactions

Avoid/Use Alternative

gepotidacin + diltiazem

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• disopyramide
Blujepa (gepotidacin)

+

disopyramide

1 interaction

Avoid/Use Alternative

gepotidacin + disopyramide

use alternative or monitor disopyramide levels, ECG, electrolytes: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dofetilide
Blujepa (gepotidacin)

+

dofetilide

1 interaction

Avoid/Use Alternative

gepotidacin + dofetilide

use alternative or monitor ECG, electrolytes: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• domperidone
Blujepa (gepotidacin)

+

domperidone

1 interaction

Avoid/Use Alternative

gepotidacin + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• donepezil
Blujepa (gepotidacin)

+

donepezil

2 interactions

Avoid/Use Alternative

gepotidacin + donepezil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• dordaviprone
Blujepa (gepotidacin)

+

dordaviprone

1 interaction

Avoid/Use Alternative

gepotidacin + dordaviprone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dronedarone
Blujepa (gepotidacin)

+

dronedarone

1 interaction

Avoid/Use Alternative

gepotidacin + dronedarone

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• droperidol
Blujepa (gepotidacin)

+

droperidol

1 interaction

Avoid/Use Alternative

gepotidacin + droperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• duvelisib
Blujepa (gepotidacin)

+

duvelisib

1 interaction

Avoid/Use Alternative

gepotidacin + duvelisib

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• efavirenz
Blujepa (gepotidacin)

+

efavirenz

2 interactions

Avoid/Use Alternative

gepotidacin + efavirenz

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• encorafenib
Blujepa (gepotidacin)

+

encorafenib

1 interaction

Avoid/Use Alternative

gepotidacin + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. gepotidacin levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• enzalutamide
Blujepa (gepotidacin)

+

enzalutamide

1 interaction

Avoid/Use Alternative

gepotidacin + enzalutamide

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• ephedra
Blujepa (gepotidacin)

+

ephedra

1 interaction

Avoid/Use Alternative

gepotidacin + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Blujepa (gepotidacin)

+

epirubicin

2 interactions

Avoid/Use Alternative

gepotidacin + epirubicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eribulin
Blujepa (gepotidacin)

+

eribulin

1 interaction

Avoid/Use Alternative

gepotidacin + eribulin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Blujepa (gepotidacin)

+

erythromycin

1 interaction

Avoid/Use Alternative

gepotidacin + erythromycin

use alternative or monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• etravirine
Blujepa (gepotidacin)

+

etravirine

1 interaction

Avoid/Use Alternative

gepotidacin + etravirine

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• fecal microbiota, live
Blujepa (gepotidacin)

+

fecal microbiota, live

1 interaction

Avoid/Use Alternative

gepotidacin + fecal microbiota, live

ORAL MICROBIOTA: avoid combo; RECTAL MICROBIOTA: avoid combo up to 8wk after admin.: combo may decr. gut microbiota restoration (antibiotic effects)

• fedratinib
Blujepa (gepotidacin)

+

fedratinib

1 interaction

Avoid/Use Alternative

gepotidacin + fedratinib

ALL INDICATIONS: if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs; UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• fexinidazole
Blujepa (gepotidacin)

+

fexinidazole

2 interactions

Avoid/Use Alternative

gepotidacin + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after gepotidacin D/C; UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: use alternative or monitor ECG, electrolytes during and x7 days after fexinidazole tx: combo may decr. fexinidazole active metabolite levels, efficacy; may decr. gepotidacin levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. inhibited, decr. conversion to active metabolites; hepatic metab. induced; additive effects)

• flecainide
Blujepa (gepotidacin)

+

flecainide

1 interaction

Avoid/Use Alternative

gepotidacin + flecainide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluconazole
Blujepa (gepotidacin)

+

fluconazole

1 interaction

Avoid/Use Alternative

gepotidacin + fluconazole

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• fluorouracil
Blujepa (gepotidacin)

+

fluorouracil

1 interaction

Avoid/Use Alternative

gepotidacin + fluorouracil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosamprenavir
Blujepa (gepotidacin)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

gepotidacin + fosamprenavir

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• fosfomycin injection
Blujepa (gepotidacin)

+

fosfomycin injection

2 interactions

Avoid/Use Alternative

gepotidacin + fosfomycin injection

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosphenytoin
Blujepa (gepotidacin)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

gepotidacin + fosphenytoin

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• gentamicin
Blujepa (gepotidacin)

+

gentamicin

1 interaction

Avoid/Use Alternative

gepotidacin + gentamicin

avoid combo: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, both drugs exhibit partial neuromuscular blockade)

• glasdegib
Blujepa (gepotidacin)

+

glasdegib

2 interactions

Avoid/Use Alternative

gepotidacin + glasdegib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• goserelin
Blujepa (gepotidacin)

+

goserelin

1 interaction

Avoid/Use Alternative

gepotidacin + goserelin

PROSTATE CANCER: use alternative or monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• grapefruit
Blujepa (gepotidacin)

+

grapefruit

1 interaction

Avoid/Use Alternative

gepotidacin + grapefruit

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metab. inhibited)

• haloperidol
Blujepa (gepotidacin)

+

haloperidol

1 interaction

Avoid/Use Alternative

gepotidacin + haloperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hydrocodone
Blujepa (gepotidacin)

+

hydrocodone

1 interaction

Avoid/Use Alternative

gepotidacin + hydrocodone

use alternative or monitor resp. rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• hydroxychloroquine
Blujepa (gepotidacin)

+

hydroxychloroquine

2 interactions

Avoid/Use Alternative

gepotidacin + hydroxychloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hydroxyzine
Blujepa (gepotidacin)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

gepotidacin + hydroxyzine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Blujepa (gepotidacin)

+

ibutilide

1 interaction

Avoid/Use Alternative

gepotidacin + ibutilide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• imatinib
Blujepa (gepotidacin)

+

imatinib

2 interactions

Avoid/Use Alternative

gepotidacin + imatinib

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• inotuzumab ozogamicin
Blujepa (gepotidacin)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

gepotidacin + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isavuconazonium
Blujepa (gepotidacin)

+

isavuconazonium

1 interaction

Avoid/Use Alternative

gepotidacin + isavuconazonium

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• isoflurane
Blujepa (gepotidacin)

+

isoflurane

1 interaction

Avoid/Use Alternative

gepotidacin + isoflurane

use alternative or monitor ECG, electrolytes, resp. rate: combo may incr. risk of QT prolongation, cardiac arrhythmias, resp. depression, potentiate, prolong neuromuscular blockade (additive effects, gepotidacin exhibits partial neuromuscular blockade)

• itraconazole
Blujepa (gepotidacin)

+

itraconazole

1 interaction

Avoid/Use Alternative

gepotidacin + itraconazole

use alternative or monitor ECG, electrolytes during and x2wk after itraconazole tx: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ivosidenib
Blujepa (gepotidacin)

+

ivosidenib

2 interactions

Avoid/Use Alternative

gepotidacin + ivosidenib

avoid combo: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. gepotidacin levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• ketoconazole
Blujepa (gepotidacin)

+

ketoconazole

1 interaction

Avoid/Use Alternative

gepotidacin + ketoconazole

use alternative or monitor ECG, electrolytes during and up to 1wk after ketoconazole tx: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lefamulin
Blujepa (gepotidacin)

+

lefamulin

1 interaction

Avoid/Use Alternative

gepotidacin + lefamulin

use alternative or monitor ECG, electrolytes: combo with oral lefamulin may may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; combo with IV lefamulin may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. inhibited, additive effects)

• lenacapavir
Blujepa (gepotidacin)

+

lenacapavir

1 interaction

Avoid/Use Alternative

gepotidacin + lenacapavir

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes during and x9mo after lenacapavir tx; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes during and x9mo after lenacapavir tx: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• letermovir
Blujepa (gepotidacin)

+

letermovir

2 interactions

Avoid/Use Alternative

gepotidacin + letermovir

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• leuprolide
Blujepa (gepotidacin)

+

leuprolide

1 interaction

Avoid/Use Alternative

gepotidacin + leuprolide

PROSTATE CANCER: use alternative or monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Blujepa (gepotidacin)

+

levofloxacin

1 interaction

Avoid/Use Alternative

gepotidacin + levofloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lofexidine
Blujepa (gepotidacin)

+

lofexidine

2 interactions

Avoid/Use Alternative

gepotidacin + lofexidine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lonafarnib
Blujepa (gepotidacin)

+

lonafarnib

1 interaction

Avoid/Use Alternative

gepotidacin + lonafarnib

use alternative or monitor HR, ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lopinavir/ritonavir
Blujepa (gepotidacin)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

gepotidacin + lopinavir/ ritonavir

use alternative or monitor ECG, electrolytes: combo may incr. or decr. gepotidacin levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metab. altered)

• lorlatinib
Blujepa (gepotidacin)

+

lorlatinib

1 interaction

Avoid/Use Alternative

gepotidacin + lorlatinib

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• lumacaftor/ivacaftor
Blujepa (gepotidacin)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

gepotidacin + lumacaftor/ ivacaftor

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• macimorelin
Blujepa (gepotidacin)

+

macimorelin

2 interactions

Avoid/Use Alternative

gepotidacin + macimorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mavacamten
Blujepa (gepotidacin)

+

mavacamten

1 interaction

Avoid/Use Alternative

gepotidacin + mavacamten

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: monitor cardiac fxn, incl. LVEF: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. gepotidacin levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• meperidine
Blujepa (gepotidacin)

+

meperidine

1 interaction

Avoid/Use Alternative

gepotidacin + meperidine

use alternative or monitor resp. rate, ECG: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• methotrexate
Blujepa (gepotidacin)

+

methotrexate

2 interactions

Avoid/Use Alternative

gepotidacin + methotrexate

if oral methotrexate use, consider alternative or monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects; may decr. methotrexate active metabolite levels, efficacy (decreased absorption; intestinal metab. inhibited, decr. conversion to active metabolite)

• mifepristone
Blujepa (gepotidacin)

+

mifepristone

1 interaction

Avoid/Use Alternative

gepotidacin + mifepristone

use alternative or monitor ECG, electrolytes during and x14 days after daily mifepristone use: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• mitapivat
Blujepa (gepotidacin)

+

mitapivat

1 interaction

Avoid/Use Alternative

gepotidacin + mitapivat

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• mitotane
Blujepa (gepotidacin)

+

mitotane

1 interaction

Avoid/Use Alternative

gepotidacin + mitotane

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• mobocertinib
Blujepa (gepotidacin)

+

mobocertinib

2 interactions

Avoid/Use Alternative

gepotidacin + mobocertinib

use alternative or monitor ECG, electrolytes: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• modafinil
Blujepa (gepotidacin)

+

modafinil

1 interaction

Avoid/Use Alternative

gepotidacin + modafinil

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• moxifloxacin
Blujepa (gepotidacin)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

gepotidacin + moxifloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nafcillin
Blujepa (gepotidacin)

+

nafcillin

1 interaction

Avoid/Use Alternative

gepotidacin + nafcillin

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• nelfinavir
Blujepa (gepotidacin)

+

nelfinavir

2 interactions

Avoid/Use Alternative

gepotidacin + nelfinavir

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• neomycin
Blujepa (gepotidacin)

+

neomycin

1 interaction

Avoid/Use Alternative

gepotidacin + neomycin

avoid combo: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade if compromised gut wall allows oral aminoglycoside absorption (additive effects, both drugs exhibit partial neuromuscular blockade)

• netupitant
Blujepa (gepotidacin)

+

netupitant

1 interaction

Avoid/Use Alternative

gepotidacin + netupitant

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes during and x1wk after (fos)netupitant tx; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes during and x1wk after (fos)netupitant tx: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• nilotinib
Blujepa (gepotidacin)

+

nilotinib

1 interaction

Avoid/Use Alternative

gepotidacin + nilotinib

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• nirogacestat
Blujepa (gepotidacin)

+

nirogacestat

1 interaction

Avoid/Use Alternative

gepotidacin + nirogacestat

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• oliceridine
Blujepa (gepotidacin)

+

oliceridine

2 interactions

Avoid/Use Alternative

gepotidacin + oliceridine

use alternative or monitor resp. rate, ECG, electrolytes: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ondansetron
Blujepa (gepotidacin)

+

ondansetron

1 interaction

Avoid/Use Alternative

gepotidacin + ondansetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Blujepa (gepotidacin)

+

osimertinib

1 interaction

Avoid/Use Alternative

gepotidacin + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxycodone
Blujepa (gepotidacin)

+

oxycodone

1 interaction

Avoid/Use Alternative

gepotidacin + oxycodone

use alternative or monitor resp. rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• pacritinib
Blujepa (gepotidacin)

+

pacritinib

1 interaction

Avoid/Use Alternative

gepotidacin + pacritinib

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: use alternative or monitor ECG, electrolytes, CBC, bleeding s/sx: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects; may decr. gepotidacin levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• paliperidone
Blujepa (gepotidacin)

+

paliperidone

2 interactions

Avoid/Use Alternative

gepotidacin + paliperidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Blujepa (gepotidacin)

+

palonosetron

1 interaction

Avoid/Use Alternative

gepotidacin + palonosetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paromomycin
Blujepa (gepotidacin)

+

paromomycin

1 interaction

Avoid/Use Alternative

gepotidacin + paromomycin

use alternative or monitor resp. rate: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade if compromised gut wall allows oral aminoglycoside absorption (additive effects, both drugs exhibit partial neuromuscular blockade)

• pentamidine
Blujepa (gepotidacin)

+

pentamidine

2 interactions

Avoid/Use Alternative

gepotidacin + pentamidine

use alternative or monitor ECG, electrolytes; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pentobarbital
Blujepa (gepotidacin)

+

pentobarbital

1 interaction

Avoid/Use Alternative

gepotidacin + pentobarbital

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• pexidartinib
Blujepa (gepotidacin)

+

pexidartinib

1 interaction

Avoid/Use Alternative

gepotidacin + pexidartinib

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. gepotidacin levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• phenobarbital
Blujepa (gepotidacin)

+

phenobarbital

1 interaction

Avoid/Use Alternative

gepotidacin + phenobarbital

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• phenytoin
Blujepa (gepotidacin)

+

phenytoin

2 interactions

Avoid/Use Alternative

gepotidacin + phenytoin

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• plazomicin
Blujepa (gepotidacin)

+

plazomicin

1 interaction

Avoid/Use Alternative

gepotidacin + plazomicin

use alternative or monitor resp. rate: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade if compromised gut wall allows oral aminoglycoside absorption (additive effects, both drugs exhibit partial neuromuscular blockade)

• polymyxin B
Blujepa (gepotidacin)

+

polymyxin B

1 interaction

Avoid/Use Alternative

gepotidacin + polymyxin B

avoid combo: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, both drugs exhibit partial neuromuscular blockade)

• pralsetinib
Blujepa (gepotidacin)

+

pralsetinib

1 interaction

Avoid/Use Alternative

gepotidacin + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• procainamide
Blujepa (gepotidacin)

+

procainamide

2 interactions

Avoid/Use Alternative

gepotidacin + procainamide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Blujepa (gepotidacin)

+

propafenone

1 interaction

Avoid/Use Alternative

gepotidacin + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, use alternative or monitor ECG, BP, electrolytes: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metab. inhibited, additive effects)

• quinidine (antiarrhythmic)
Blujepa (gepotidacin)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

gepotidacin + quinidine (antiarrhythmic)

use alternative or monitor quinidine levels, ECG, electrolytes: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• quinidine (CYP2D6 inhibitor)
Blujepa (gepotidacin)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

gepotidacin + quinidine (CYP2D6 inhibitor)

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Blujepa (gepotidacin)

+

quinine

2 interactions

Avoid/Use Alternative

gepotidacin + quinine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quizartinib
Blujepa (gepotidacin)

+

quizartinib

1 interaction

Avoid/Use Alternative

gepotidacin + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• repotrectinib
Blujepa (gepotidacin)

+

repotrectinib

1 interaction

Avoid/Use Alternative

gepotidacin + repotrectinib

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may incr. repotrectinib levels, risk of adverse effects; may decr. gepotidacin levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• revumenib
Blujepa (gepotidacin)

+

revumenib

1 interaction

Avoid/Use Alternative

gepotidacin + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rifabutin
Blujepa (gepotidacin)

+

rifabutin

2 interactions

Avoid/Use Alternative

gepotidacin + rifabutin

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• rifampin
Blujepa (gepotidacin)

+

rifampin

1 interaction

Avoid/Use Alternative

gepotidacin + rifampin

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• rifapentine
Blujepa (gepotidacin)

+

rifapentine

1 interaction

Avoid/Use Alternative

gepotidacin + rifapentine

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• rilzabrutinib
Blujepa (gepotidacin)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

gepotidacin + rilzabrutinib

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ritonavir
Blujepa (gepotidacin)

+

ritonavir

2 interactions

Avoid/Use Alternative

gepotidacin + ritonavir

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• rivastigmine
Blujepa (gepotidacin)

+

rivastigmine

1 interaction

Avoid/Use Alternative

gepotidacin + rivastigmine

use alternative: combo may incr. risk of cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• romidepsin
Blujepa (gepotidacin)

+

romidepsin

1 interaction

Avoid/Use Alternative

gepotidacin + romidepsin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rucaparib
Blujepa (gepotidacin)

+

rucaparib

1 interaction

Avoid/Use Alternative

gepotidacin + rucaparib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selpercatinib
Blujepa (gepotidacin)

+

selpercatinib

1 interaction

Avoid/Use Alternative

gepotidacin + selpercatinib

use alternative or monitor ECG, electrolytes: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• sevabertinib
Blujepa (gepotidacin)

+

sevabertinib

1 interaction

Avoid/Use Alternative

gepotidacin + sevabertinib

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• sevoflurane
Blujepa (gepotidacin)

+

sevoflurane

1 interaction

Avoid/Use Alternative

gepotidacin + sevoflurane

use alternative or monitor ECG, electrolytes, resp. rate: combo may incr. risk of QT prolongation, cardiac arrhythmias, resp. depression, potentiate, prolong neuromuscular blockade (additive effects, gepotidacin exhibits partial neuromuscular blockade)

• simvastatin
Blujepa (gepotidacin)

+

simvastatin

2 interactions

Avoid/Use Alternative

gepotidacin + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• sirolimus albumin-bound
Blujepa (gepotidacin)

+

sirolimus albumin-bound

1 interaction

Avoid/Use Alternative

gepotidacin + sirolimus albumin-bound

use alternative or decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• sotalol
Blujepa (gepotidacin)

+

sotalol

1 interaction

Avoid/Use Alternative

gepotidacin + sotalol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotorasib
Blujepa (gepotidacin)

+

sotorasib

1 interaction

Avoid/Use Alternative

gepotidacin + sotorasib

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• St. John's wort
Blujepa (gepotidacin)

+

St. John's wort

1 interaction

Avoid/Use Alternative

gepotidacin + St. John's wort

avoid combo: combo may decr. gepotidacin levels, efficacy (hepatic metab. induced)

• streptomycin
Blujepa (gepotidacin)

+

streptomycin

1 interaction

Avoid/Use Alternative

gepotidacin + streptomycin

avoid combo: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, both drugs exhibit partial neuromuscular blockade)

• taletrectinib
Blujepa (gepotidacin)

+

taletrectinib

1 interaction

Avoid/Use Alternative

gepotidacin + taletrectinib

use alternative or monitor ECG, electrolytes: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• telavancin
Blujepa (gepotidacin)

+

telavancin

1 interaction

Avoid/Use Alternative

gepotidacin + telavancin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tipranavir
Blujepa (gepotidacin)

+

tipranavir

2 interactions

Avoid/Use Alternative

gepotidacin + tipranavir

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• tobramycin
Blujepa (gepotidacin)

+

tobramycin

1 interaction

Avoid/Use Alternative

gepotidacin + tobramycin

avoid combo: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, both drugs exhibit partial neuromuscular blockade)

• tobramycin inhaled
Blujepa (gepotidacin)

+

tobramycin inhaled

1 interaction

Avoid/Use Alternative

gepotidacin + tobramycin inhaled

avoid combo: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, both drugs exhibit partial neuromuscular blockade)

• toremifene
Blujepa (gepotidacin)

+

toremifene

1 interaction

Avoid/Use Alternative

gepotidacin + toremifene

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tramadol
Blujepa (gepotidacin)

+

tramadol

1 interaction

Avoid/Use Alternative

gepotidacin + tramadol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triclabendazole
Blujepa (gepotidacin)

+

triclabendazole

2 interactions

Avoid/Use Alternative

gepotidacin + triclabendazole

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Blujepa (gepotidacin)

+

trifluridine

1 interaction

Avoid/Use Alternative

gepotidacin + trifluridine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triptorelin
Blujepa (gepotidacin)

+

triptorelin

1 interaction

Avoid/Use Alternative

gepotidacin + triptorelin

PROSTATE CANCER: use alternative or monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tucatinib
Blujepa (gepotidacin)

+

tucatinib

1 interaction

Avoid/Use Alternative

gepotidacin + tucatinib

use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• typhoid vaccine, live
Blujepa (gepotidacin)

+

typhoid vaccine, live

1 interaction

Avoid/Use Alternative

gepotidacin + typhoid vaccine, live

avoid vaccine course during and w/in 72h of gepotidacin use; if possible, delay gepotidacin until at least 72h after last vaccine dose: combo may result in inadequate vaccine response (antibiotic effect may inactivate vaccine)

• vandetanib
Blujepa (gepotidacin)

+

vandetanib

2 interactions

Avoid/Use Alternative

gepotidacin + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vemurafenib
Blujepa (gepotidacin)

+

vemurafenib

1 interaction

Avoid/Use Alternative

gepotidacin + vemurafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• verapamil
Blujepa (gepotidacin)

+

verapamil

1 interaction

Avoid/Use Alternative

gepotidacin + verapamil

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, AV block, other adverse effects (hepatic metab. inhibited)

• ziftomenib
Blujepa (gepotidacin)

+

ziftomenib

2 interactions

Avoid/Use Alternative

gepotidacin + ziftomenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ziprasidone
Blujepa (gepotidacin)

+

ziprasidone

1 interaction

Avoid/Use Alternative

gepotidacin + ziprasidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

• abemaciclib
Blujepa (gepotidacin)

+

abemaciclib

1 interaction

Monitor/Modify Tx

gepotidacin + abemaciclib

monitor CBC: combo may incr. abemaciclib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• acalabrutinib
Blujepa (gepotidacin)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

gepotidacin + acalabrutinib

monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• alfentanil
Blujepa (gepotidacin)

+

alfentanil

2 interactions

Monitor/Modify Tx

gepotidacin + alfentanil

monitor resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited)

• atorvastatin
Blujepa (gepotidacin)

+

atorvastatin

1 interaction

Monitor/Modify Tx

gepotidacin + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport inhibited)

• avanafil
Blujepa (gepotidacin)

+

avanafil

1 interaction

Monitor/Modify Tx

gepotidacin + avanafil

monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• avapritinib
Blujepa (gepotidacin)

+

avapritinib

1 interaction

Monitor/Modify Tx

gepotidacin + avapritinib

monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metab. inhibited)

• botulinum toxin
Blujepa (gepotidacin)

+

botulinum toxin

1 interaction

Monitor/Modify Tx

gepotidacin + botulinum toxin

monitor resp. rate: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, both drugs exhibit partial neuromuscular blockade)

• brigatinib
Blujepa (gepotidacin)

+

brigatinib

2 interactions

Monitor/Modify Tx

gepotidacin + brigatinib

monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metab. inhibited)

• capivasertib
Blujepa (gepotidacin)

+

capivasertib

1 interaction

Monitor/Modify Tx

gepotidacin + capivasertib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• clozapine
Blujepa (gepotidacin)

+

clozapine

1 interaction

Monitor/Modify Tx

gepotidacin + clozapine

monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metab. inhibited)

• digoxin
Blujepa (gepotidacin)

+

digoxin

1 interaction

Monitor/Modify Tx

gepotidacin + digoxin

monitor digoxin levels, HR: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• docetaxel
Blujepa (gepotidacin)

+

docetaxel

1 interaction

Monitor/Modify Tx

gepotidacin + docetaxel

monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• entrectinib
Blujepa (gepotidacin)

+

entrectinib

2 interactions

Monitor/Modify Tx

gepotidacin + entrectinib

monitor ECG: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• eplerenone
Blujepa (gepotidacin)

+

eplerenone

1 interaction

Monitor/Modify Tx

gepotidacin + eplerenone

monitor potassium: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited)

• everolimus
Blujepa (gepotidacin)

+

everolimus

1 interaction

Monitor/Modify Tx

gepotidacin + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• exenatide
Blujepa (gepotidacin)

+

exenatide

1 interaction

Monitor/Modify Tx

gepotidacin + exenatide

give gepotidacin at least 1h before twice daily exenatide; caution w/ weekly exenatide: combo may decr. peak gepotidacin levels, efficacy (absorption delayed, possibly decreased)

• felodipine
Blujepa (gepotidacin)

+

felodipine

2 interactions

Monitor/Modify Tx

gepotidacin + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metab. inhibited)

• fentanyl
Blujepa (gepotidacin)

+

fentanyl

1 interaction

Monitor/Modify Tx

gepotidacin + fentanyl

monitor resp. rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• finerenone
Blujepa (gepotidacin)

+

finerenone

1 interaction

Monitor/Modify Tx

gepotidacin + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited)

• flibanserin
Blujepa (gepotidacin)

+

flibanserin

1 interaction

Monitor/Modify Tx

gepotidacin + flibanserin

monitor BP, especially if flibanserin also combined w/ other weak CYP3A4 inhibitors: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metab. inhibited)

• gepirone
Blujepa (gepotidacin)

+

gepirone

1 interaction

Monitor/Modify Tx

gepotidacin + gepirone

monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• histrelin
Blujepa (gepotidacin)

+

histrelin

2 interactions

Monitor/Modify Tx

gepotidacin + histrelin

consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ibrutinib
Blujepa (gepotidacin)

+

ibrutinib

1 interaction

Monitor/Modify Tx

gepotidacin + ibrutinib

consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ivabradine
Blujepa (gepotidacin)

+

ivabradine

1 interaction

Monitor/Modify Tx

gepotidacin + ivabradine

monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ixabepilone
Blujepa (gepotidacin)

+

ixabepilone

1 interaction

Monitor/Modify Tx

gepotidacin + ixabepilone

monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited)

• lemborexant
Blujepa (gepotidacin)

+

lemborexant

1 interaction

Monitor/Modify Tx

gepotidacin + lemborexant

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lixisenatide
Blujepa (gepotidacin)

+

lixisenatide

2 interactions

Monitor/Modify Tx

gepotidacin + lixisenatide

give gepotidacin at least 1h before lixisenatide: combo may decr. peak gepotidacin levels, efficacy (absorption delayed, possibly decreased)

• lomitapide
Blujepa (gepotidacin)

+

lomitapide

1 interaction

Monitor/Modify Tx

gepotidacin + lomitapide

adjust max lomitapide dose to 30 mg/day: combo may incr. lomitapide levels, risk of adverse effects (hepatic metab. inhibited)

• lovastatin
Blujepa (gepotidacin)

+

lovastatin

1 interaction

Monitor/Modify Tx

gepotidacin + lovastatin

monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• lumateperone
Blujepa (gepotidacin)

+

lumateperone

1 interaction

Monitor/Modify Tx

gepotidacin + lumateperone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lurasidone
Blujepa (gepotidacin)

+

lurasidone

1 interaction

Monitor/Modify Tx

gepotidacin + lurasidone

monitor ECG: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lurbinectedin
Blujepa (gepotidacin)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

gepotidacin + lurbinectedin

monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• midazolam
Blujepa (gepotidacin)

+

midazolam

2 interactions

Monitor/Modify Tx

gepotidacin + midazolam

monitor resp. rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• morphine
Blujepa (gepotidacin)

+

morphine

1 interaction

Monitor/Modify Tx

gepotidacin + morphine

monitor resp. rate: combo may incr. morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

• nifedipine
Blujepa (gepotidacin)

+

nifedipine

1 interaction

Monitor/Modify Tx

gepotidacin + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nimodipine
Blujepa (gepotidacin)

+

nimodipine

1 interaction

Monitor/Modify Tx

gepotidacin + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nisoldipine
Blujepa (gepotidacin)

+

nisoldipine

1 interaction

Monitor/Modify Tx

gepotidacin + nisoldipine

monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• pemigatinib
Blujepa (gepotidacin)

+

pemigatinib

1 interaction

Monitor/Modify Tx

gepotidacin + pemigatinib

monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• pramlintide
Blujepa (gepotidacin)

+

pramlintide

2 interactions

Monitor/Modify Tx

gepotidacin + pramlintide

give gepotidacin at least 1h before or 2h after pramlintide: combo may decr. peak gepotidacin levels, efficacy (absorption delayed)

• red yeast rice
Blujepa (gepotidacin)

+

red yeast rice

1 interaction

Monitor/Modify Tx

gepotidacin + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, red yeast rice contains varying amounts of lovastatin)

• sirolimus
Blujepa (gepotidacin)

+

sirolimus

1 interaction

Monitor/Modify Tx

gepotidacin + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• succinylcholine
Blujepa (gepotidacin)

+

succinylcholine

1 interaction

Monitor/Modify Tx

gepotidacin + succinylcholine

monitor resp. rate: combo may incr. risk of resp. depression, potentiate, prolong neuromuscular blockade (additive effects, gepotidacin exhibits partial neuromuscular blockade)

• sufentanil
Blujepa (gepotidacin)

+

sufentanil

1 interaction

Monitor/Modify Tx

gepotidacin + sufentanil

monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• tacrolimus
Blujepa (gepotidacin)

+

tacrolimus

2 interactions

Monitor/Modify Tx

gepotidacin + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• tadalafil
Blujepa (gepotidacin)

+

tadalafil

1 interaction

Monitor/Modify Tx

gepotidacin + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• temsirolimus
Blujepa (gepotidacin)

+

temsirolimus

1 interaction

Monitor/Modify Tx

gepotidacin + temsirolimus

monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• triazolam
Blujepa (gepotidacin)

+

triazolam

2 interactions

Monitor/Modify Tx

gepotidacin + triazolam

monitor resp. rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ubrogepant
Blujepa (gepotidacin)

+

ubrogepant

1 interaction

Monitor/Modify Tx

gepotidacin + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metab. inhibited)

• vardenafil
Blujepa (gepotidacin)

+

vardenafil

1 interaction

Monitor/Modify Tx

gepotidacin + vardenafil

monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• venetoclax
Blujepa (gepotidacin)

+

venetoclax

1 interaction

Monitor/Modify Tx

gepotidacin + venetoclax

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited)

• vinblastine
Blujepa (gepotidacin)

+

vinblastine

1 interaction

Monitor/Modify Tx

gepotidacin + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vincristine
Blujepa (gepotidacin)

+

vincristine

2 interactions

Monitor/Modify Tx

gepotidacin + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vinorelbine
Blujepa (gepotidacin)

+

vinorelbine

1 interaction

Monitor/Modify Tx

gepotidacin + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• warfarin
Blujepa (gepotidacin)

+

warfarin

1 interaction

Monitor/Modify Tx

gepotidacin + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metab. inhibited, alteration of vitamin K producing gut flora)

• zanubrutinib
Blujepa (gepotidacin)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

gepotidacin + zanubrutinib

monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection; myelosuppression, other adverse effects (hepatic metab. inhibited)

Caution Advised

• aclidinium inhaled
Blujepa (gepotidacin)

+

aclidinium inhaled

2 interactions

Caution Advised

gepotidacin + aclidinium inhaled

caution advised: combo may decr. aclidinium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• amantadine
Blujepa (gepotidacin)

+

amantadine

1 interaction

Caution Advised

gepotidacin + amantadine

caution advised: combo may decr. amantadine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• amifampridine
Blujepa (gepotidacin)

+

amifampridine

1 interaction

Caution Advised

gepotidacin + amifampridine

caution advised: combo may incr. risk of cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• atracurium
Blujepa (gepotidacin)

+

atracurium

1 interaction

Caution Advised

gepotidacin + atracurium

caution advised: combo may decr. atracurium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• atropine
Blujepa (gepotidacin)

+

atropine

2 interactions

Caution Advised

gepotidacin + atropine

caution advised: combo may decr. atropine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• belladonna alkaloids
Blujepa (gepotidacin)

+

belladonna alkaloids

1 interaction

Caution Advised

gepotidacin + belladonna alkaloids

caution advised: combo may decr. belladonna alkaloids efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• benztropine
Blujepa (gepotidacin)

+

benztropine

1 interaction

Caution Advised

gepotidacin + benztropine

caution advised: combo may decr. benztropine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• bethanechol
Blujepa (gepotidacin)

+

bethanechol

1 interaction

Caution Advised

gepotidacin + bethanechol

caution advised: combo may incr. risk of cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• cariprazine
Blujepa (gepotidacin)

+

cariprazine

1 interaction

Caution Advised

gepotidacin + cariprazine

caution advised: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)

• cevimeline
Blujepa (gepotidacin)

+

cevimeline

2 interactions

Caution Advised

gepotidacin + cevimeline

caution advised: combo may incr. risk of cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• cisatracurium
Blujepa (gepotidacin)

+

cisatracurium

1 interaction

Caution Advised

gepotidacin + cisatracurium

caution advised: combo may decr. cisatracurium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• clidinium
Blujepa (gepotidacin)

+

clidinium

1 interaction

Caution Advised

gepotidacin + clidinium

caution advised: combo may decr. clidinium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• cobimetinib
Blujepa (gepotidacin)

+

cobimetinib

1 interaction

Caution Advised

gepotidacin + cobimetinib

caution advised: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metab. inhibited)

• cyclophosphamide
Blujepa (gepotidacin)

+

cyclophosphamide

1 interaction

Caution Advised

gepotidacin + cyclophosphamide

caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy (hepatic metab. possibly inhibited, decr. conversion to active metabolite)

• daridorexant
Blujepa (gepotidacin)

+

daridorexant

2 interactions

Caution Advised

gepotidacin + daridorexant

caution advised: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• darifenacin
Blujepa (gepotidacin)

+

darifenacin

1 interaction

Caution Advised

gepotidacin + darifenacin

caution advised: combo may decr. darifenacin efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• dicyclomine
Blujepa (gepotidacin)

+

dicyclomine

1 interaction

Caution Advised

gepotidacin + dicyclomine

caution advised: combo may decr. dicyclomine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• dihydroergotamine
Blujepa (gepotidacin)

+

dihydroergotamine

1 interaction

Caution Advised

gepotidacin + dihydroergotamine

caution advised: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• dulaglutide
Blujepa (gepotidacin)

+

dulaglutide

2 interactions

Caution Advised

gepotidacin + dulaglutide

caution advised: combo may decr. peak gepotidacin levels, efficacy (absorption delayed, possibly decreased)

• elinzanetant
Blujepa (gepotidacin)

+

elinzanetant

1 interaction

Caution Advised

gepotidacin + elinzanetant

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ergotamine
Blujepa (gepotidacin)

+

ergotamine

1 interaction

Caution Advised

gepotidacin + ergotamine

caution advised: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• fesoterodine
Blujepa (gepotidacin)

+

fesoterodine

1 interaction

Caution Advised

gepotidacin + fesoterodine

caution advised: combo may decr. fesoterodine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• flavoxate
Blujepa (gepotidacin)

+

flavoxate

2 interactions

Caution Advised

gepotidacin + flavoxate

caution advised: combo may decr. flavoxate efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• galantamine
Blujepa (gepotidacin)

+

galantamine

1 interaction

Caution Advised

gepotidacin + galantamine

caution advised: combo may incr. risk of cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• glycopyrrolate
Blujepa (gepotidacin)

+

glycopyrrolate

1 interaction

Caution Advised

gepotidacin + glycopyrrolate

caution advised: combo may decr. glycopyrrolate efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• glycopyrrolate inhaled
Blujepa (gepotidacin)

+

glycopyrrolate inhaled

1 interaction

Caution Advised

gepotidacin + glycopyrrolate inhaled

caution advised: combo may decr. glycopyrrolate efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• glycopyrronium topical
Blujepa (gepotidacin)

+

glycopyrronium topical

1 interaction

Caution Advised

gepotidacin + glycopyrronium topical

caution advised: combo may decr. glycopyrronium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• homatropine
Blujepa (gepotidacin)

+

homatropine

2 interactions

Caution Advised

gepotidacin + homatropine

caution advised: combo may decr. homatropine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• hyoscyamine
Blujepa (gepotidacin)

+

hyoscyamine

1 interaction

Caution Advised

gepotidacin + hyoscyamine

caution advised: combo may decr. hyoscyamine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• ipratropium inhaled
Blujepa (gepotidacin)

+

ipratropium inhaled

1 interaction

Caution Advised

gepotidacin + ipratropium inhaled

caution advised: combo may decr. ipratropium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• lactulose
Blujepa (gepotidacin)

+

lactulose

1 interaction

Caution Advised

gepotidacin + lactulose

caution advised: combo may decr. lactulose efficacy (colonic metab. inhibited)

• liraglutide
Blujepa (gepotidacin)

+

liraglutide

1 interaction

Caution Advised

gepotidacin + liraglutide

caution advised: combo may decr. peak gepotidacin levels, efficacy (absorption delayed, possibly decreased)

• methacholine inhaled
Blujepa (gepotidacin)

+

methacholine inhaled

2 interactions

Caution Advised

gepotidacin + methacholine inhaled

caution advised: combo may incr. risk of cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• methscopolamine
Blujepa (gepotidacin)

+

methscopolamine

1 interaction

Caution Advised

gepotidacin + methscopolamine

caution advised: combo may decr. methscopolamine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• methylergonovine
Blujepa (gepotidacin)

+

methylergonovine

1 interaction

Caution Advised

gepotidacin + methylergonovine

caution advised: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• neostigmine
Blujepa (gepotidacin)

+

neostigmine

1 interaction

Caution Advised

gepotidacin + neostigmine

caution advised: combo may incr. risk of cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• oxybutynin
Blujepa (gepotidacin)

+

oxybutynin

2 interactions

Caution Advised

gepotidacin + oxybutynin

caution advised: combo may decr. oxybutynin efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• palovarotene
Blujepa (gepotidacin)

+

palovarotene

1 interaction

Caution Advised

gepotidacin + palovarotene

caution advised: combo may incr. palovarotene levels, risk of adverse effects (hepatic metab. inhibited)

• pilocarpine
Blujepa (gepotidacin)

+

pilocarpine

1 interaction

Caution Advised

gepotidacin + pilocarpine

caution advised: combo may incr. risk of cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• pyridostigmine
Blujepa (gepotidacin)

+

pyridostigmine

1 interaction

Caution Advised

gepotidacin + pyridostigmine

caution advised: combo may incr. risk of cholinergic adverse effects (additive effects, gepotidacin reversibly inhibits acetylcholinesterase)

• revefenacin inhaled
Blujepa (gepotidacin)

+

revefenacin inhaled

2 interactions

Caution Advised

gepotidacin + revefenacin inhaled

caution advised: combo may decr. revefenacin efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• rocuronium
Blujepa (gepotidacin)

+

rocuronium

1 interaction

Caution Advised

gepotidacin + rocuronium

caution advised: combo may decr. rocuronium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• roflumilast
Blujepa (gepotidacin)

+

roflumilast

1 interaction

Caution Advised

gepotidacin + roflumilast

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

• roflumilast topical
Blujepa (gepotidacin)

+

roflumilast topical

1 interaction

Caution Advised

gepotidacin + roflumilast topical

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

• scopolamine
Blujepa (gepotidacin)

+

scopolamine

2 interactions

Caution Advised

gepotidacin + scopolamine

caution advised: combo may decr. scopolamine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• sirolimus topical
Blujepa (gepotidacin)

+

sirolimus topical

1 interaction

Caution Advised

gepotidacin + sirolimus topical

caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metab. inhibited)

• sodium picosulfate
Blujepa (gepotidacin)

+

sodium picosulfate

1 interaction

Caution Advised

gepotidacin + sodium picosulfate

caution advised: combo may decr. sodium picosulfate efficacy (colonic metab. inhibited, decr. conversion to active metabolite)

• sofpironium topical
Blujepa (gepotidacin)

+

sofpironium topical

1 interaction

Caution Advised

gepotidacin + sofpironium topical

caution advised: combo may decr. sofpironium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• solifenacin
Blujepa (gepotidacin)

+

solifenacin

1 interaction

Caution Advised

gepotidacin + solifenacin

caution advised: combo may decr. solifenacin efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• tiotropium inhaled
Blujepa (gepotidacin)

+

tiotropium inhaled

1 interaction

Caution Advised

gepotidacin + tiotropium inhaled

caution advised: combo may decr. tiotropium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• tirzepatide
Blujepa (gepotidacin)

+

tirzepatide

2 interactions

Caution Advised

gepotidacin + tirzepatide

caution advised: combo may decr. peak gepotidacin levels, efficacy (absorption delayed, possibly decreased)

• tolterodine
Blujepa (gepotidacin)

+

tolterodine

1 interaction

Caution Advised

gepotidacin + tolterodine

caution advised: combo may decr. tolterodine efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• trihexyphenidyl
Blujepa (gepotidacin)

+

trihexyphenidyl

1 interaction

Caution Advised

gepotidacin + trihexyphenidyl

caution advised: combo may decr. trihexyphenidyl efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• trospium
Blujepa (gepotidacin)

+

trospium

1 interaction

Caution Advised

gepotidacin + trospium

caution advised: combo may decr. trospium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• umeclidinium inhaled
Blujepa (gepotidacin)

+

umeclidinium inhaled

1 interaction

Caution Advised

gepotidacin + umeclidinium inhaled

caution advised: combo may decr. umeclidinium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

• vecuronium
Blujepa (gepotidacin)

+

vecuronium

1 interaction

Caution Advised

gepotidacin + vecuronium

caution advised: combo may decr. vecuronium efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)